Cargando…
MIF Contributes to Trypanosoma brucei Associated Immunopathogenicity Development
African trypanosomiasis is a chronic debilitating disease affecting the health and economic well-being of many people in developing countries. The pathogenicity associated with this disease involves a persistent inflammatory response, whereby M1-type myeloid cells, including Ly6C(high) inflammatory...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177988/ https://www.ncbi.nlm.nih.gov/pubmed/25255103 http://dx.doi.org/10.1371/journal.ppat.1004414 |
_version_ | 1782336872337375232 |
---|---|
author | Stijlemans, Benoît Leng, Lin Brys, Lea Sparkes, Amanda Vansintjan, Liese Caljon, Guy Raes, Geert Van Den Abbeele, Jan Van Ginderachter, Jo A. Beschin, Alain Bucala, Richard De Baetselier, Patrick |
author_facet | Stijlemans, Benoît Leng, Lin Brys, Lea Sparkes, Amanda Vansintjan, Liese Caljon, Guy Raes, Geert Van Den Abbeele, Jan Van Ginderachter, Jo A. Beschin, Alain Bucala, Richard De Baetselier, Patrick |
author_sort | Stijlemans, Benoît |
collection | PubMed |
description | African trypanosomiasis is a chronic debilitating disease affecting the health and economic well-being of many people in developing countries. The pathogenicity associated with this disease involves a persistent inflammatory response, whereby M1-type myeloid cells, including Ly6C(high) inflammatory monocytes, are centrally implicated. A comparative gene analysis between trypanosusceptible and trypanotolerant animals identified MIF (macrophage migrating inhibitory factor) as an important pathogenic candidate molecule. Using MIF-deficient mice and anti-MIF antibody treated mice, we show that MIF mediates the pathogenic inflammatory immune response and increases the recruitment of inflammatory monocytes and neutrophils to contribute to liver injury in Trypanosoma brucei infected mice. Moreover, neutrophil-derived MIF contributed more significantly than monocyte-derived MIF to increased pathogenic liver TNF production and liver injury during trypanosome infection. MIF deficient animals also featured limited anemia, coinciding with increased iron bio-availability, improved erythropoiesis and reduced RBC clearance during the chronic phase of infection. Our data suggest that MIF promotes the most prominent pathological features of experimental trypanosome infections (i.e. anemia and liver injury), and prompt considering MIF as a novel target for treatment of trypanosomiasis-associated immunopathogenicity. |
format | Online Article Text |
id | pubmed-4177988 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-41779882014-10-02 MIF Contributes to Trypanosoma brucei Associated Immunopathogenicity Development Stijlemans, Benoît Leng, Lin Brys, Lea Sparkes, Amanda Vansintjan, Liese Caljon, Guy Raes, Geert Van Den Abbeele, Jan Van Ginderachter, Jo A. Beschin, Alain Bucala, Richard De Baetselier, Patrick PLoS Pathog Research Article African trypanosomiasis is a chronic debilitating disease affecting the health and economic well-being of many people in developing countries. The pathogenicity associated with this disease involves a persistent inflammatory response, whereby M1-type myeloid cells, including Ly6C(high) inflammatory monocytes, are centrally implicated. A comparative gene analysis between trypanosusceptible and trypanotolerant animals identified MIF (macrophage migrating inhibitory factor) as an important pathogenic candidate molecule. Using MIF-deficient mice and anti-MIF antibody treated mice, we show that MIF mediates the pathogenic inflammatory immune response and increases the recruitment of inflammatory monocytes and neutrophils to contribute to liver injury in Trypanosoma brucei infected mice. Moreover, neutrophil-derived MIF contributed more significantly than monocyte-derived MIF to increased pathogenic liver TNF production and liver injury during trypanosome infection. MIF deficient animals also featured limited anemia, coinciding with increased iron bio-availability, improved erythropoiesis and reduced RBC clearance during the chronic phase of infection. Our data suggest that MIF promotes the most prominent pathological features of experimental trypanosome infections (i.e. anemia and liver injury), and prompt considering MIF as a novel target for treatment of trypanosomiasis-associated immunopathogenicity. Public Library of Science 2014-09-25 /pmc/articles/PMC4177988/ /pubmed/25255103 http://dx.doi.org/10.1371/journal.ppat.1004414 Text en © 2014 Stijlemans et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Stijlemans, Benoît Leng, Lin Brys, Lea Sparkes, Amanda Vansintjan, Liese Caljon, Guy Raes, Geert Van Den Abbeele, Jan Van Ginderachter, Jo A. Beschin, Alain Bucala, Richard De Baetselier, Patrick MIF Contributes to Trypanosoma brucei Associated Immunopathogenicity Development |
title | MIF Contributes to Trypanosoma brucei Associated Immunopathogenicity Development |
title_full | MIF Contributes to Trypanosoma brucei Associated Immunopathogenicity Development |
title_fullStr | MIF Contributes to Trypanosoma brucei Associated Immunopathogenicity Development |
title_full_unstemmed | MIF Contributes to Trypanosoma brucei Associated Immunopathogenicity Development |
title_short | MIF Contributes to Trypanosoma brucei Associated Immunopathogenicity Development |
title_sort | mif contributes to trypanosoma brucei associated immunopathogenicity development |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177988/ https://www.ncbi.nlm.nih.gov/pubmed/25255103 http://dx.doi.org/10.1371/journal.ppat.1004414 |
work_keys_str_mv | AT stijlemansbenoit mifcontributestotrypanosomabruceiassociatedimmunopathogenicitydevelopment AT lenglin mifcontributestotrypanosomabruceiassociatedimmunopathogenicitydevelopment AT bryslea mifcontributestotrypanosomabruceiassociatedimmunopathogenicitydevelopment AT sparkesamanda mifcontributestotrypanosomabruceiassociatedimmunopathogenicitydevelopment AT vansintjanliese mifcontributestotrypanosomabruceiassociatedimmunopathogenicitydevelopment AT caljonguy mifcontributestotrypanosomabruceiassociatedimmunopathogenicitydevelopment AT raesgeert mifcontributestotrypanosomabruceiassociatedimmunopathogenicitydevelopment AT vandenabbeelejan mifcontributestotrypanosomabruceiassociatedimmunopathogenicitydevelopment AT vanginderachterjoa mifcontributestotrypanosomabruceiassociatedimmunopathogenicitydevelopment AT beschinalain mifcontributestotrypanosomabruceiassociatedimmunopathogenicitydevelopment AT bucalarichard mifcontributestotrypanosomabruceiassociatedimmunopathogenicitydevelopment AT debaetselierpatrick mifcontributestotrypanosomabruceiassociatedimmunopathogenicitydevelopment |